Russo, G. L., Majem, M., O'Byrne, K. J., Goetze, T. O., Mueller, C., Triebel, F. (2025). TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8668